Restoring accommodation

Article

Ophthalmology is perhaps two steps closer to a possible clinical application of lens refilling with silicon gel for restoring ocular accommodation thanks to a refined procedure developed by Dr Okihiro Nishi, MD of the Nishi Eye Hospital, Japan.

Ophthalmology is perhaps two steps closer to a possible clinical application of lens refilling with silicon gel for restoring ocular accommodation thanks to a refined procedure developed by Dr Okihiro Nishi, MD of the Nishi Eye Hospital, Japan.

“Refilling the lens capsule while preserving capsular integrity offers the potential to restore ocular accommodation,” he told a large audience at the Ridley Medal Lecture.

In his recent work he and his team had solved two of the most persistent problems currently impeding progress in the lens refilling technique, namely leakage of the silicon gel and capsular opacification. “It is really amazing; the accommodative IOL seals such a large CCC opening and prevents leakage,” he said.

“The procedure may be an alternative to the multifocal and accommodating IOLs for treating presbyopia,” he added.

 

To read OTE's full news coverage of the XXVI congress of the European Society of Cataract & Refractive Surgery, please click here.

Recent Videos
Thomas Aaberg, MD, gives an update on Neurotech Pharmaceuticals NT-501 device for the potential treatment of retinitis pigmentosa and age-related macular degeneration, including a projected PDUFA date from the FDA at the annual ASRS meeting in Stockholm, Sweden.
Sruthi Arepalli, MD, spoke with Modern Retina about her presentation, "Assessing retinal vascular changes in alzheimer disease with radiomics: A preliminary study of fundus photography" at the annual ASRS meeting in Stockholm, Sweden.
Nathan Steinle, MD, spoke with Modern Retina about the ongoing research on the durability of sozinibercept in combination therapy with anti-VEGF-A treatments at the annual ASRS meeting in Stockholm, Sweden.
Deepak Sambhara, MD, shared an overview of his paper-on-demand, which covered real-world safety and efficacy of aflibercept, 8 mg in the treatment of neovascular age-related macular degeneration at the annual ASRS meeting in Stockholm, Sweden.
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
© 2024 MJH Life Sciences

All rights reserved.